Prognostic Value of Hepatocyte Growth Factor for Muscle-invasive Bladder Cancer release_ff5fojq5l5cezicp5tg5kygc5e

by Satoshi Katayama, Victor M. Schuettfort, Benjamin Pradere, Keiichiro Mori, Hadi Mostafaei, Fahad Quhal, Reza Sari Motlagh, Ekaterina Laukhtina, Nico C. Grossmann, Abdulmajeed Aydh, Pawel Rajwa, Frederik König (+11 others)

Released as a post by Research Square Platform LLC.

2021  

Abstract

<jats:title>Abstract</jats:title> PurposeThe HGF/MET pathway is involved in cell motility, angiogenesis, proliferation, and cancer invasion. We assessed the clinical utility of plasma HGF level as a prognostic biomarker in patients with MIBC.MethodsWe retrospectively analyzed 565 patients with MIBC who underwent radical cystectomy. Logistic regression and Cox regression models were used, and predictive accuracies were estimated using the area under the curve and concordance index. To estimate the clinical utility of HGF, DCA and MCID were applied.ResultsPlasma HGF level was significantly higher in patients with advanced pathologic stage and LN metastasis (<jats:italic>p</jats:italic>=0.01 and <jats:italic>p</jats:italic>&lt;0.001, respectively). Higher HGF levels were associated with an increased risk of harboring LN metastasis and non-organ-confined disease (OR1.21, 95%CI 1.12-1.32, <jats:italic>p</jats:italic>&lt;0.001, and OR1.35, 95%CI 1.23-1.48, <jats:italic>p</jats:italic>&lt;0.001, respectively) on multivariable analyses; the addition of HGF improved the predictive accuracies of a standard preoperative model (+7%, <jats:italic>p</jats:italic>&lt;0.001 and +8%, <jats:italic>p</jats:italic>&lt;0.001, respectively). According to the DCA and MCID, half of the patients had a net benefit by including HGF, but the absolute magnitude remained limited. In pre- and postoperative predictive models, a higher HGF level was significant prognosticator of worse RFS, OS, and CSS; in the preoperative model, the addition of HGF improved accuracies by 6% and 5% for RFS and CSS, respectively.ConclusionPreoperative HGF identified MIBC patients who harbored features of clinically and biologically aggressive disease. Plasma HGF could serve, as part of a panel, as a biomarker to aid in preoperative treatment planning regarding intensity of treatment in patients with clinically MIBC.
In application/xml+jats format

Archived Files and Locations

application/pdf   511.2 kB
file_d6o6ccl4qfb3zpz3x57qkdj72u
assets.researchsquare.com (publisher)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  post
Stage   unknown
Date   2021-09-27
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 6caa011c-251e-4a43-865b-9c17f0435304
API URL: JSON